Mounjaro Heart Benefits: The New FDA Heart Indication Explained

If you take Mounjaro, or your doctor just brought it up, you may have heard it now "protects the heart." Is that true, and what does it mean for you? Short answer: on August 28, 2026, the FDA added a heart indication to the Mounjaro (tirzepatide) label. It says Mounjaro lowers the risk of major heart events in adults with type 2 diabetes who are at high risk. The proof is a large 4-year trial called SURPASS-CVOT. Lilly listed the approval among its third-quarter highlights on October 29, 2026.

This guide explains what the trial found, who the indication covers, the heart side effects on the label, and how Mounjaro stacks up against other GLP-1 drugs with heart claims.

What is the Mounjaro heart indication?

The Mounjaro label now lists two uses:

1. Along with diet and exercise, to improve blood sugar in adults and children 10 years and older with type 2 diabetes.
2. To lower the risk of major adverse cardiovascular events (often shortened to MACE) in adults with type 2 diabetes who are at high risk for those events.

MACE means three things: cardiovascular death, a heart attack that does not kill you, and a stroke that does not kill you. Doctors use this trio to measure whether a drug protects the heart and blood vessels.

The heart use is only for people who also have type 2 diabetes. It is not a heart drug for everyone, and it does not replace blood pressure pills, statins or aspirin your doctor prescribed.

What SURPASS-CVOT showed

Most heart trials compare a drug with a dummy shot (placebo). SURPASS-CVOT did something harder. It compared Mounjaro with Trulicity (dulaglutide), a GLP-1 drug that had already been shown to lower heart events. That makes it one of the toughest tests a diabetes drug has faced.

In plain English: Mounjaro was at least as good as a drug that already protects the heart. The trend leaned in Mounjaro's favor, but not by enough to call it better. Deaths from any cause were lower on Mounjaro, yet the investigators said that finding needs more study before anyone leans on it. The results were published in the New England Journal of Medicine.

Is Mounjaro heart protective without diabetes?

The FDA has not said so. The indication is written for adults with type 2 diabetes. Zepbound is the same drug (tirzepatide) sold for weight loss and sleep apnea, and it does not have a heart indication. Its own heart trial, SURMOUNT-MMO, enrolls about 15,000 adults with obesity and no diabetes. ClinicalTrials.gov lists an estimated primary completion date of October 2027.

If you are on Zepbound for weight, the weight loss itself may help your blood pressure and blood sugar. But there is no approved heart claim yet. Our Zepbound vs Mounjaro guide explains why one drug has two brand names and two labels.

Mounjaro vs other GLP-1 drugs with heart claims

Several GLP-1 drugs now carry a heart indication. Each earned it in a different trial, against a different comparison, in a different group of people.

You cannot rank these drugs from this table. A trial against placebo and a trial against another active drug answer different questions. For the bigger picture on SELECT and the rest, see our GLP-1 and cardiovascular health guide.

Mounjaro heart rate and palpitations

The label reports that Mounjaro raised average heart rate by 2 to 4 beats per minute in trials. People on placebo went up by about 1 beat per minute. Other GLP-1 drugs show a similar small rise.

Most people will not notice a change that small. Some people do report a racing or pounding heart, and dehydration from vomiting or diarrhea can make it worse. Call your doctor if:

• Your heart races, pounds or skips beats and it does not settle.
• You feel dizzy, short of breath or faint.
• You have chest pain. Chest pain, fainting or trouble breathing needs emergency care, not a wait-and-see.

Mounjaro also has a boxed warning about thyroid C-cell tumors seen in rodents, plus warnings for pancreatitis, low blood sugar when used with insulin or sulfonylureas, and kidney problems from dehydration. The most common side effects in SURPASS-CVOT were stomach problems, mostly mild to moderate and mostly while the dose was going up. Dose steps are on the label and in our Mounjaro dosage chart. Your prescriber decides your dose.

Why muscle matters for the heart benefit

Weight loss on tirzepatide is not all fat. Some of it is lean tissue, and muscle is what keeps you strong enough to stay active. Staying active is one of the best things you can do for your heart. People also ask whether these drugs shrink the heart muscle itself; we covered what the research says in our GLP-1 heart muscle loss guide.

Two habits protect skeletal muscle while the scale drops: enough protein every day and regular strength training. Sharpy turns that into one daily protein target and one 20-minute workout, and its Shape Score shows whether you are losing fat, not muscle. If your lifts start falling, our guide to how strength numbers should move on GLP-1 helps you read the signs.

Questions to ask your doctor

• Do I count as "high risk" for heart events under the new label?
• Should Mounjaro change any of my other heart medicines? (Do not stop or change them on your own.)
• How will we watch my heart rate and blood pressure?
• If I am on Zepbound, should I be on Mounjaro instead, given my diabetes status?
• What should I do if I have palpitations or chest pain?

Bottom line

Mounjaro heart benefits are now on the FDA label for adults with type 2 diabetes at high risk. SURPASS-CVOT showed it is at least as good as Trulicity at preventing heart attack, stroke and heart death, with a trend in its favor. The indication does not extend to Zepbound or to weight loss without diabetes, at least until SURMOUNT-MMO reports. Whatever drug you take, protein and strength work help you keep the muscle that keeps you moving. Sharpy tracks both in one place. For the basics of the drug itself, start with our Mounjaro guide.

Sources

• DailyMed: Mounjaro (tirzepatide) prescribing information, revised August 2026
• Pharmacy Times: FDA approves tirzepatide to cut CV risk in type 2 diabetes (Aug 28, 2026)
• Eli Lilly Q3 2026 results, SEC Form 8-K exhibit (Oct 29, 2026)
• Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025;393:2409-2420 (NEJM CME summary)
• TCTMD: SURPASS-CVOT published
• Healio: Tirzepatide similar to dulaglutide for CV outcomes but tied to lower rates of death
• ClinicalTrials.gov: SURMOUNT-MMO (NCT05556512)